Kim Su Jin, Jeon Seung Hwan, Kwon Eun Bi, Jeong Hyun Cheol, Choi Sae Woong, Bae Woong Jin, Cho Hyuk Jin, Ha U Syn, Hong Sung Hoo, Lee Ji Youl, Hwang Sung Yeoun, Kim Sae Woong
Department of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Urology, Institute of Biomedical Industry, The Catholic University of Korea, Seoul, Korea.
World J Mens Health. 2018 May;36(2):153-160. doi: 10.5534/wjmh.17010. Epub 2017 Oct 25.
Many patients with benign prostatic hyperplasia need treatment for remaining storage symptoms after surgery. Therefore, we evaluated the effect of the phytotherapeutic agent WSY-1075 on persistent detrusor overactivity (DO) after the relief of bladder outlet obstruction (BOO).
Rats were assigned to 3 groups: control (n=6), persistent DO (n=6), and persistent DO treated with the phytotherapeutic agent WSY-1075 (n=6). Persistent DO after relief of partial BOO was generated in the rat model, and 6 of the rats with this condition were orally administered WSY-1075. After 4 weeks of administration, cystometry was performed. Additionally, 8-hydroxy-2-deoxyguanosine and superoxide dismutase were measured to evaluate oxidative stress in the bladder. Pro-inflammatory cytokines, such as interleukin-8 and tumor necrosis factor-α, were analyzed, as were the M2 and M3 muscarinic receptors of the bladder.
Significantly increased contraction pressure and a decreased contraction interval were observed in the persistent DO group after relief of BOO. Moreover, oxidative stress, pro-inflammatory cytokines, and M3 muscarinic receptors were significantly increased. After treatment with WSY-1075, significantly reduced DO was observed by cystometry in comparison with the persistent DO group. Additionally, significantly decreased levels of oxidative stress, pro-inflammatory cytokines, and M3 muscarinic receptors in the bladder were observed after treatment with WSY-1075.
Treatment with WSY-1075 improved persistent DO after the relief of BOO mediated by antioxidative and anti-inflammatory effects. Further studies are necessary to identify the exact mechanism of the treatment effect of WSY-1075.
许多良性前列腺增生患者术后仍有储尿期症状需要治疗。因此,我们评估了植物治疗剂WSY - 1075对膀胱出口梗阻(BOO)解除后持续性逼尿肌过度活动(DO)的影响。
将大鼠分为3组:对照组(n = 6)、持续性DO组(n = 6)和用植物治疗剂WSY - 1075治疗的持续性DO组(n = 6)。在大鼠模型中造成部分BOO解除后的持续性DO,其中6只患有这种情况的大鼠口服WSY - 1075。给药4周后,进行膀胱测压。此外,测量8 - 羟基 - 2 - 脱氧鸟苷和超氧化物歧化酶以评估膀胱中的氧化应激。分析促炎细胞因子,如白细胞介素 - 8和肿瘤坏死因子 - α,以及膀胱的M2和M3毒蕈碱受体。
BOO解除后,持续性DO组的收缩压显著升高,收缩间隔缩短。此外,氧化应激、促炎细胞因子和M3毒蕈碱受体显著增加。用WSY - 1075治疗后,膀胱测压显示与持续性DO组相比,DO显著降低。此外,用WSY - 1075治疗后,膀胱中的氧化应激、促炎细胞因子和M3毒蕈碱受体水平显著降低。
WSY - 1075治疗通过抗氧化和抗炎作用改善了BOO解除后的持续性DO。需要进一步研究以确定WSY - 1075治疗效果的确切机制。